Pharmacokinetic-Pharmacodynamic (PK-PD) Model for Tolvaptan in Patients with Hypervolemic Hyponatremia

被引：0
|
作者：
Van Wart, Scott [1 ]
Shoaf, Susan [2 ]
Mallikaarjun, Suresh [2 ]
Mager, Donald [1 ]
机构：
[1] SUNY Buffalo, Buffalo, NY 14260 USA
[2] Otsuka, Rockville, MD USA
来源：
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS | 2015年 / 42卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
W-06
引用
收藏
页码：S76 / S76
页数：1
相关论文
共 50 条
  • [21] PHARMACOKINETIC-PHARMACODYNAMIC PARAMETER ESTIMATION: APPLICATION OF GENETIC ALGORITHMS FOR PK-PD PARAMETER ESTIMATION
    Das, Shyam S.
    Bahl, Jyotsna
    Narayanan, Ramamurthi
    DRUG METABOLISM REVIEWS, 2015, 47 : 228 - 229
  • [22] A Microfluidic Perfusion Platform for In Vitro Analysis of Drug Pharmacokinetic-Pharmacodynamic (PK-PD) Relationships
    Guerrero, Yadir A.
    Desai, Diti
    Sullivan, Connor
    Kindt, Erick
    Spilker, Mary E.
    Maurer, Tristan S.
    Solomon, Deepak E.
    Bartlett, Derek W.
    AAPS JOURNAL, 2020, 22 (02):
  • [23] Concerns about pharmacokinetic (PK) and pharmacokinetic-pharmacodynamic (PK-PD) studies in the new therapeutic area of COVID-19 infection
    Venisse, Nicolas
    Peytavin, Gilles
    Bouchet, Stephane
    Gagnieu, Marie-Claude
    Garraffo, Rodolphe
    Guilhaumou, Romain
    Solas, Caroline
    ANTIVIRAL RESEARCH, 2020, 181
  • [24] The role of mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modelling in translational research of biologics
    Agoram, Balaji M.
    Martin, Steven W.
    van der Graaf, Piet H.
    DRUG DISCOVERY TODAY, 2007, 12 (23-24) : 1018 - 1024
  • [25] Pharmacokinetic/pharmacodynamic (PK/PD) model for tolvaptan (TOL) in healthy subjects.
    Van Wart, SA
    Cirincione, BB
    Ludwig, EA
    Chen, X
    Shoaf, S
    Grasela, TH
    Mallikaarjun, S
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 79 (02) : P60 - P60
  • [26] Pharmacokinetic-pharmacodynamic (PK-PD) modeling of cardiovascular effects of metoprolol in spontaneously hypertensive rats: a microdialysis study
    Christian Höcht
    Carla Di Verniero
    Javier A. W. Opezzo
    Guillermo F. Bramuglia
    Carlos A. Taira
    Naunyn-Schmiedeberg's Archives of Pharmacology, 2006, 373 : 310 - 318
  • [27] Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling and simulation of oxaliplatin for hematological toxicity in rats
    Kobuchi, Shinji
    Katsuyama, Yosuke
    Ito, Yukako
    XENOBIOTICA, 2020, 50 (02) : 146 - 153
  • [28] The pharmacokinetic-pharmacodynamic (PK-PD) relationship of pasireotide (SOM230), a novel somatostatin analogue, in patients with acromegaly.
    Lee, Lucy
    Glusman, J.
    Gao, B.
    Buchelt, A.
    Deckert, F.
    Schran, H.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 46 (09): : 1086 - 1086
  • [29] Pharmacokinetic-pharmacodynamic (PK-PD) modeling of cardiovascular effects of metoprolol in spontaneously hypertensive rats:: a microdialysis study
    Hocht, Christian
    Di Verniero, Carla
    Opezzo, Javier A. W.
    Bramuglia, Guillermo F.
    Taira, Carlos A.
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2006, 373 (04) : 310 - 318
  • [30] Pharmacokinetic-pharmacodynamic (Pk-Pd) modeling of entecavir: Prediction of log decrease in hepatitis B viral load
    Fiske, W
    Olsen, S
    Yan, JH
    Grasela, D
    Phillips, L
    Owen, J
    HEPATOLOGY, 2002, 36 (04) : 631A - 631A
12345